White Paper

Accelerating Generic Approvals: 5 Keys To Being First To Market

Source: BASi (Bioanalytical Systems Inc)

At a time when many of the most successful drugs are reaching the patent cliff, opening the floodgates for generic substitutes, generic companies are rushing to target the best candidates and enter the market first. And they are relying more heavily than ever on qualified outsource product development partners.

Competition in the generics market has never been greater. As patents on pharmaceutical products with sales of more than $267B expire over the next six years, companies worldwide are seizing the opportunity to introduce a generic alternative and rigorously competing to be first to market.